Shanghai Jiaotong University Yang Xuanming's team discovered a new target for CAR-T treatment of T-cell malignant tumors

Recently, the internationally important academic journal "Nature Communications" published online the research results "T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies" by Yang Xuanming's team from Sheng Yushou Cell and Immunology Research Center of Shanghai Jiao Tong University

CAR-T therapy is an effective therapy for the treatment of hematological tumors in recent years.

Yang Xuanming's research team has long been committed to the development of tumor immunotherapy, and has carried out preclinical and clinical researches such as antibody therapy and cell therapy

Figure 1.

This research project was supported by the National Natural Science Foundation of China (81971467), the National Key R&D Program (2016YFC1303400), the Science and Technology Innovation Fund of Shanghai Jiaotong University (2019QYA11), and the General Funding of China Postdoctoral Science Foundation (2022M712073)

Paper link: